LINC02101

Across TCGA pan-cancer cohorts, LINC02101 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of LINC02101’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC02101 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC02101 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

BRCA, LUSC, and LIHC are the cancer types where LINC02101 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC02101 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	Female	II,III,IV	−0.184	<.001	6	view →
LUSC	All	II,III,IV	−0.140	<.001	5	view →
LIHC	Male	All	+0.160	.002	4	view →
PRAD	All	All	+0.118	.001	2	view →
KICH	All	All	−0.079	.022	2	view →
KIRC	All	All	+0.071	.005	2	view →
CHOL	All	All	+0.103	.037	1	view →
THCA	Female	III,IV	+0.086	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

LINC02101–BRCA

Open the BRCA breakdown →